Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.41 -1.1%	$9.02	$7.11 ▼ $30.19	$438.26M	-0.05	656,014 shs	600,301 shs
FTLF FitLife Brands	$10.40 -9.5%	$14.36	$10.40 ▼ $17.75	$95.88M	0.8	17,390 shs	36,689 shs
MNMD Mind Medicine (MindMed)	$5.43 -2.2%	$7.12	$4.93 ▼ $11.36	$409.25M	2.57	1.40 million shs	2.67 million shs
RLAY Relay Therapeutics	$2.00 -12.7%	$3.60	$1.99 ▼ $10.72	$339.04M	1.7	1.89 million shs	3.24 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-1.07%	-7.61%	-12.10%	-41.56%	-56.92%
FTLF FitLife Brands	-9.49%	-17.53%	-30.99%	-35.08%	-17.88%
MNMD Mind Medicine (MindMed)	-2.16%	-12.28%	-14.89%	-24.37%	-53.79%
RLAY Relay Therapeutics	-12.66%	-26.47%	-41.00%	-54.75%	-71.99%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.9659 of 5 stars	3.5	0.0	3.1	2.5	0.6
FTLF FitLife Brands	4.3818 of 5 stars	3.7	5.0	2.5	3.3	3.1
MNMD Mind Medicine (MindMed)	2.1276 of 5 stars	3.6	2.0	2.9	0.8	0.6
RLAY Relay Therapeutics	2.0593 of 5 stars	3.5	1.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$32.86	343.42% Upside
FTLF FitLife Brands	3.33	Buy	$20.50	97.12% Upside
MNMD Mind Medicine (MindMed)	3.23	Buy	$25.11	362.45% Upside
RLAY Relay Therapeutics	2.90	Moderate Buy	$19.80	890.00% Upside

Current Analyst Ratings Breakdown

Latest FTLF, RLAY, CGEM, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/17/2025	FTLF FitLife Brands	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
3/7/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$38.00 ➝ $35.00
3/7/2025	MNMD Mind Medicine (MindMed)	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$27.00 ➝ $16.00
3/7/2025	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
3/7/2025	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
2/28/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
2/27/2025	RLAY Relay Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
2/27/2025	RLAY Relay Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $23.00
1/31/2025	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
1/29/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
1/28/2025	MNMD Mind Medicine (MindMed)	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$23.00

(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
FTLF FitLife Brands	$64.47M	1.49	$0.55 per share	19.05	$3.04 per share	3.42
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
RLAY Relay Therapeutics	$10.01M	33.88	N/A	N/A	$5.90 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$3.03	N/A	N/A	N/A	N/A	-26.54%	-25.32%	5/13/2025 (Estimated)
FTLF FitLife Brands	$5.30M	$0.84	12.31	9.45	N/A	13.38%	28.03%	15.13%	N/A
MNMD Mind Medicine (MindMed)	-$95.73M	-$2.08	N/A	N/A	N/A	N/A	-47.56%	-35.55%	5/6/2025 (Estimated)
RLAY Relay Therapeutics	-$341.97M	-$2.39	N/A	N/A	N/A	N/A	-45.75%	-40.75%	5/1/2025 (Estimated)

Latest FTLF, RLAY, CGEM, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	RLAY Relay Therapeutics	-$0.51	N/A	N/A	N/A	$0.01 million	N/A
3/27/2025	Q4	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A
2/27/2025	Q4 2024	CGEM Cullinan Therapeutics	-$0.75	-$0.73	+$0.02	-$0.73	N/A	N/A
2/26/2025	Q4 2024	RLAY Relay Therapeutics	-$0.57	-$0.45	+$0.12	-$0.45	$5.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
FTLF FitLife Brands	0.28	1.50	0.64
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
RLAY Relay Therapeutics	N/A	18.42	18.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
FTLF FitLife Brands	2.32%
MNMD Mind Medicine (MindMed)	27.91%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	6.07%
FTLF FitLife Brands	61.30%
MNMD Mind Medicine (MindMed)	2.26%
RLAY Relay Therapeutics	4.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	58.51 million	54.69 million	Optionable
FTLF FitLife Brands	20	9.22 million	3.56 million	Not Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable
RLAY Relay Therapeutics	330	169.52 million	160.15 million	Optionable

FTLF, RLAY, CGEM, and MNMD Headlines

Recent News About These Companies

Relay Therapeutics

April 3 at 5:50 AM | forbes.com

Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook

April 2 at 2:42 PM | investing.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 4,864 Shares

April 1, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $13,813.76 in Stock

April 1, 2025 | insidertrades.com

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

March 31, 2025 | msn.com

Analysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $19.80

March 30, 2025 | americanbankingnews.com

Relay Therapeutics weakness brings buying opportunity, says Barclays

March 28, 2025 | markets.businessinsider.com

Relay Therapeutics (NASDAQ:RLAY) Trading 6.1% Higher - Should You Buy?

March 28, 2025 | marketbeat.com

BIT Capital GmbH Acquires New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

March 28, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

March 27, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - What's Next?

March 26, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - Should You Sell?

March 20, 2025 | marketbeat.com

Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition

March 19, 2025 | investing.com

Relay Therapeutics (NASDAQ:RLAY) Trading Down 6.7% - Should You Sell?

March 14, 2025 | marketbeat.com

Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges

March 14, 2025 | investing.com

HC Wainwright Reaffirms Buy Rating for Relay Therapeutics (NASDAQ:RLAY)

March 8, 2025 | marketbeat.com

Candriam S.C.A. Acquires 636,494 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

March 8, 2025 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Should You Sell?

March 6, 2025 | marketbeat.com

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

March 5, 2025 | zacks.com

Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP

February 28, 2025 | markets.businessinsider.com

Bank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF, RLAY, CGEM, and MNMD Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.41 -0.08 (-1.07%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$7.42 +0.01 (+0.13%)

As of 04/4/2025 04:49 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

FitLife Brands NASDAQ:FTLF

$10.40 -1.09 (-9.49%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$10.54 +0.15 (+1.39%)

As of 04/4/2025 04:05 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Mind Medicine (MindMed) NASDAQ:MNMD

$5.43 -0.12 (-2.16%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$5.48 +0.04 (+0.83%)

As of 04/4/2025 07:53 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Relay Therapeutics NASDAQ:RLAY

$2.00 -0.29 (-12.66%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.05 (+2.50%)

As of 04/4/2025 07:56 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time